Navigation Links
Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
Date:5/18/2009

NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today reported unaudited financial results for the quarter ended March 31, 2009.

    Highlights
    -- Total revenue increased to RMB442.5 million (US$64.8 million) for the
       first quarter of 2009 from RMB394.6 million for the corresponding
       period in 2008, representing 12.1% year-over-year growth.
    -- Income from operations was RMB61.1 million (US$8.9 million) for the
       first quarter of 2009, a decrease of 38.4% from RMB99.2 million for the
       corresponding period in 2008.
    -- Net income attributable to Simcere was RMB48.2 million (US$7.1 million)
       for the first quarter of 2009, representing a 57.0% year-over-year
       decrease.
    -- Gross margin for the first quarter of 2009 was 82.5%, compared to 83.2%
       for the corresponding period in 2008.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, commented: "We saw solid growth in our total revenue this quarter. Sales of our edaravone injection products, the single largest contributor to our total revenue, continued to grow, while the sales performance of Endu remained a challenge. Elsewhere in our portfolio, the growth of Sinofuan and our other branded generics was encouraging."

Mr. Ren continued, "We are excited to announce today our partnership with Shanghai Celgen, a developer and producer of antibodies. Following our recent agreement with Epitomics, this is an important step forward in developing Simcere's strategic focus in the area of biopharmaceuticals. Looking forward, we will continue to seek investment and cooperation opportunities to enrich our pipel
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009
2. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
3. Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009
4. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
5. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
6. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
7. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
8. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
9. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
10. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
11. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... The ... 7.76% of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). On ... offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 ...
(Date:6/30/2015)... 2015  Custom Computer Specialists, Inc. ("Custom"), a leading ... silver sponsors of the Primary Care Development Corporation,s ("PCDC") ... lending their support of PCDC,s mission to expand access ... its founding in 1993, PCDC has been a key ... has financed over 100 completed primary care projects, valued ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... 14. She has accepted the position of vice president of instruction at Chippewa ... , “I greatly appreciated the opportunity to lead SIUE during the past ...
(Date:6/29/2015)... NY (PRWEB) , ... June 30, 2015 , ... This ... and Perkin Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the world’s ... machine is in spec deep into the NIR range. Previous spectrophotometer calibration standards, such ...
Breaking Biology Technology:Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... Campbell Alliance, the leading management consulting firm specializing in ... launched a new practice area focused on medical affairs. ... practice enables the firm to specifically target the evolving needs ... firm has done work in the area of medical affairs ...
... OSLO, Norway, June 17 , ... Improve Remission Rates and,Reduce Short-Term Mortality Compared to Previous ... (OSE: CLAVIS) today announces positive final results,from a Phase ... in patients with late-stage acute myeloid leukaemia (AML). In ...
... Nearly 200 Quantitative Immunoassays for Discovery and Validation ... Texas, June 17 Rules-Based Medicine, Incorporated (RBM), ... announced the availability of the most comprehensive collection ... efficacy and efficiency in drug and diagnostic development. ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... NEW YORK -- Water vapor and clouds are the ... atmosphere-ocean climate modeling study shows that the planet,s temperature ... The study, conducted by Andrew Lacis and ... in New York, examined the nature of Earth,s greenhouse ...
... University of British Columbia today welcomed the announcement of ... Health Research (CIHR) and Genome British Columbia for research ... led by UBC researchers Brett Finlay and Deborah Money, ... today in Toronto by federal Health Minister Leona Aglukkaq. ...
... Cancer Research congratulates 12 of its members on their election ... new members and five foreign associates. Considered among ... the award recognizes individuals who have demonstrated outstanding professional achievement ... medicine. "This is a great day for cancer ...
Cached Biology News:Carbon dioxide controls Earth's temperature 2Carbon dioxide controls Earth's temperature 3The AACR congratulates its members elected to the Institute of Medicine 2
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Biology Products: